Dr. Laura Esserman and Dr. Steve Birrell are changing the breast cancer treatment paradigm through their collaboration on an I-SPY trial, which is reevaluating the treatment of DCIS.
Since 1993, Dr. Esserman has worked at UCSF as a surgeon and oncology specialist and co-lead of their Breast Oncology Program. She’s published over 400 peer-reviewed articles, including the New York Times, where she published an editorial on whether Ductal Carcinoma in SITU should still be called cancer. In 2016, she was named one of TIME magazine’s 100 Most Influential People. She was also a member of President Obama’s Council of Advisors on Science and Technology.
Dr. Steve Birrell is the Founder of HAVAH Therapeutics based in Adelaide, Australia. His three-decade career in cancer spans many roles. He’s a specialist, surgeon, medical innovator, and one of the most published molecular oncologists. Havah is developing a potentially revolutionary testosterone-based approach to the treatment of breast cancer.
